Urologas - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 22,895 | 54,085 | 76,200 | 140,481 | 112,287 | 127,985 | 177,972 | 227,962 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | 10,121 | 24,486 | 28,459 | 44,207 | 21,354 | 20,428 | 24,421 | 31,703 |
| Equity | 10,910 | 35,396 | 40,326 | 45,687 | 37,630 | 41,294 | 52,774 | 46,830 |
| Liabilities | 10,600 | 3,383 | 22,222 | 25,295 | 24,471 | 29,417 | 32,666 | 42,260 |
| Non-current assets | 7,362 | 4,602 | 19,334 | 12,334 | 10,971 | 8,257 | 4,443 | 3,192 |
| Current assets | 14,148 | 34,163 | 43,104 | 58,279 | 50,483 | 62,408 | 80,997 | 85,801 |
| Total assets | 21,510 | 38,765 | 62,438 | 70,613 | 61,454 | 70,665 | 85,440 | 88,993 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 8,652 | 13,658 | 18,747 |
| Social insurance contributions | - | - | - | - | - | 2,889 | 3,059 | - |
|
Financial indicators
|
||||||||
| Revenue change y/y | +252.2% | +136.2% | +40.9% | +84.4% | -20.1% | +14.0% | +39.1% | +28.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 47.1% | 63.2% | 45.6% | 62.6% | 34.7% | 28.9% | 28.6% | 35.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 92.8% | 69.2% | 70.6% | 96.8% | 56.7% | 49.5% | 46.3% | 67.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 44.2% | 45.3% | 37.3% | 31.5% | 19.0% | 16.0% | 13.7% | 13.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.0 | 0.1 | 0.6 | 0.6 | 0.7 | 0.7 | 0.6 | 0.9 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 22,895 | 43,268 | 33,867 | 46,827 | 46,463 | 43,880 | 53,392 | 75,987 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Urologas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-09-17 | 2024-09-22 | 0.20 |
| 2024-08-19 | 2024-09-09 | 0.20 |
| 2024-07-24 | 2024-08-11 | 0.20 |
| 2024-05-16 | 2024-05-19 | 0.23 |
| 2024-04-23 | 2024-05-06 | 0.23 |
| 2024-04-16 | 2024-04-18 | 60.68 |
| 2023-12-18 | 2023-12-18 | 122.33 |
| 2023-11-16 | 2023-11-20 | 0.15 |
| 2023-10-27 | 2023-11-12 | 0.15 |
| 2023-10-25 | 2023-10-25 | 0.15 |
| 2023-09-18 | 2023-09-20 | 9.58 |
| 2023-08-17 | 2023-09-04 | 10.04 |
Urologas - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-05-19 | 2026-05-26 | 175.0 |
| 2026-05-06 | 2026-05-18 | 0.06 |
| 2026-05-01 | 2026-05-05 | 92.16 |
| 2026-04-30 | 2026-04-30 | 92.1 |
| 2026-04-11 | 2026-04-13 | 178.27 |
| 2026-04-01 | 2026-04-10 | 1.8 |
| 2026-03-20 | 2026-04-01 | 0.66 |
| 2026-03-11 | 2026-03-17 | 707.15 |
| 2026-03-02 | 2026-03-10 | 245.66 |
| 2026-02-21 | 2026-03-01 | 245.0 |
| 2026-01-01 | 2026-02-03 | 0.6 |
| 2025-12-12 | 2025-12-23 | 177.96 |
| 2025-12-05 | 2025-12-11 | 1.48 |
| 2025-12-01 | 2025-12-04 | 176.82 |
| 2025-11-28 | 2025-11-30 | 176.48 |
| 2025-11-25 | 2025-11-27 | 108.48 |
| 2025-11-02 | 2025-11-02 | 8.55 |
| 2025-10-21 | 2025-11-01 | 705.98 |
| 2025-10-02 | 2025-10-20 | 0.1 |
| 2025-09-28 | 2025-10-01 | 68.0 |
| 2025-09-01 | 2025-09-11 | 0.02 |
| 2025-04-28 | 2025-05-13 | 0.01 |
| 2025-03-28 | 2025-04-22 | 0.01 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Urologas, UAB (code 300604548) is a Private Limited Liability Company engaged in medical specialists activities. In the latest financial year, 2025, the company generated revenue of €228.0K and net profit of €31.7K, resulting in a profit margin of 13.9%. Revenue increased from €128.0K in 2023 to €178.0K in 2024 and then to €228.0K in 2025, showing steady growth over the period. Net profit also improved from €20.4K in 2023 to €24.4K in 2024 and €31.7K in 2025. The balance sheet remained moderate in size, with total assets of €89.0K at the end of 2025, including €85.8K in short-term assets and €3.2K in long-term assets. Equity stood at €46.8K and liabilities at €42.3K, with an equity ratio of 52.6% and debt-to-equity of 0.90. Return on equity was 67.7% and return on assets 35.6%, supported by asset turnover of 2.56x. Revenue per employee was €76.0K and profit per employee €10.6K.